New fluoroquinolones in community-acquired pneumonia: a clinical and economic evaluation
Metge C J, Vercaigne L, Carrie A, Zhanel G G
Record ID 32002000301
English, French
Authors' objectives:
This report aims to critically review and compare, both clinically and economically, the new fluoroquinolones for the empiric treatment of community-acquired pneumonia (CAP).
Authors' recommendations:
Analysis of the trials on an intention-to-treat basis, which preserves the value of randomization and prevents the introduction of bias, indicates that the orally-administered new fluoroquinolones offer no statistically significant additional clinical successes when compared to current comparative antibiotics for the empirical treatment of CAP. The 'evaluable subjects' analysis found new fluoroquinolones to be slightly more effective in treating individuals diagnosed with CAP than comparative antibiotics. However, considering the limitations associated with the available evidence, we conclude that the new fluoroquinolones are at least as effective as, and may be slightly more effective than, comparator antibiotics for the treatment of empiric CAP. Finally, our review did not point to any overall differences in terms of serious adverse effects, but these would be unlikely to occur in relatively small studies.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/
Year Published:
2001
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Community-Acquired Infections
- Costs and Cost Analysis
- Pneumonia
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.